Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30

$0.61−0.06 (-8.25%)

Close on Nov 13, 2026Market cap $354.83KP/E –Yield –

Virax Biolabs EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Virax Biolabs has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Virax Biolabs's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Jun 26, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VRAX.

Operating margin-51515.2% · median -913114.9%

Net margin-40439.1% · median -871894.3%

Advertisement
300 × 250

See a number that looks wrong?